Pegylated interferon
Showing 1 - 25 of 2,185
Polycythemia Vera Trial in Tianjin (Ruxolitinib, Pegylated interferon a-2b)
Recruiting
- Polycythemia Vera
- Ruxolitinib
- Pegylated interferon α-2b
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
May 19, 2023
Essential Thrombocytopenia Trial in Tianjin (Recombinant Interferon Alpha, Pegylated interferon alfa-2b)
Recruiting
- Essential Thrombocytopenia
- Recombinant Interferon Alpha
- Pegylated interferon alfa-2b
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jul 18, 2022
Myelofibrosis Trial in Salt Lake City (Pegylated interferon alpha2a)
Not yet recruiting
- Myelofibrosis
- Pegylated interferon alpha2a
-
Salt Lake City, UtahHuntsman Cancer Institute at the University of Utah
Sep 6, 2022
COVID-19, COVID Trial in Boston (Pegylated interferon lambda)
Terminated
- COVID-19
- COVID
- Pegylated interferon lambda
-
Boston, MassachusettsMassachusetts General Hospital
Jun 29, 2022
Malignant Melanoma Trial in San Diego, Memphis, Houston (Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b)
Active, not recruiting
- Malignant Melanoma
- Peginterferon alfa-2b
- +2 more
-
San Diego, California
- +2 more
Apr 1, 2022
Lymphoma, B-Cell Trial in Guangzhou (Rituximab Biosimilar, Pegylated Interferon a-2b)
Recruiting
- Lymphoma, B-Cell
- Rituximab Biosimilar
- Pegylated Interferon α-2b
-
Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Ce
Apr 6, 2022
Hepatitis D, Chronic Trial in Israel, New Zealand, Pakistan (Peginterferon Lambda-1A)
Completed
- Hepatitis D, Chronic
- Peginterferon Lambda-1A
-
Beersheba, Israel
- +3 more
Dec 20, 2022
Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas Trial in Atlanta (Pegylated interferon alpha-2b)
Completed
- Juvenile Pilocytic Astrocytomas
- Optic Pathway Gliomas
- Pegylated interferon alpha-2b
-
Atlanta, GeorgiaChildren's Healthcare of Atlanta
Jan 18, 2022
Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b
Recruiting
- Hepatocellular Carcinoma
- Anti-PD-1/PD-L1
- PEG-Interferon Alfa
-
Shanghai, ChinaZhongshan Hospital, Fudan University
Mar 28, 2022
COVID-19 Trial in Be'er Sheva (Lambda 180 mcg S.C)
Recruiting
- COVID-19
- Lambda 180 mcg S.C
-
Be'er Sheva, IsraelSoroka UMC
Jan 27, 2022
Chronic Hepatitis B Trial in Zhengzhou (PegIFN a- 2b)
Completed
- Chronic Hepatitis B
- PegIFN α- 2b
-
Zhengzhou, Henan, ChinaHenan Provincial People's Hospital
Jul 11, 2022
Chronic Hepatitis b Trial in Guangzhou (Vitamin D)
Completed
- Chronic Hepatitis b
- Vitamin D
-
Guangzhou, Guangdong, ChinaDepartment of Infectious Diseases, The Third Affliated Hospital
Mar 2, 2023
Chronic Hepatitis B Trial in Shanghai (Hepalatide, Placebo of Hepalatide, Tenofovir Alafenamide Tablets)
Not yet recruiting
- Chronic Hepatitis B
- Hepalatide
- +3 more
-
Shanghai, Shanghai, China
- +1 more
Feb 16, 2022
Essential Thrombocythemia Trial (Bomedemstat, Anagrelide, Busulfan)
Not yet recruiting
- Essential Thrombocythemia
- Bomedemstat
- +4 more
- (no location specified)
Oct 6, 2023
Chronic Hepatitis B Trial in Zhengzhou (continuous treatment, pulse therapy)
Recruiting
- Chronic Hepatitis B
- continuous treatment
- pulse therapy
-
Zhengzhou, Henan, ChinaHenan Provincial People's Hospital
Jul 13, 2022
Chronic Hepatitis B Trial in Worldwide (VIR-2218, pegylated interferon-alfa 2a)
Active, not recruiting
- Chronic Hepatitis B
- VIR-2218
- pegylated interferon-alfa 2a
-
Birtinya, Queensland, Australia
- +21 more
Dec 20, 2021
Angiosarcoma Trial in Houston (Paclitaxel, mRNA plus Lysate-loaded Dendritic Cell Vaccine, PEGYLATED-INTERFERON ALPHA-2A)
Not yet recruiting
- Angiosarcoma
- Paclitaxel
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Mar 23, 2023
Hepatitis B, Chronic Trial in Beijing (Hepalatide 2.1mg, Hepalatide 4.2mg, Hepalatide 6.3mg)
Recruiting
- Hepatitis B, Chronic
- Hepalatide 2.1mg
- +6 more
-
Beijing, Beijing, ChinaThe fifth medical center of PLA
Nov 23, 2021
Hepatitis B, Chronic Trial in Hefei (PEGylated recombinant human interferon alpha-2b injection)
Recruiting
- Hepatitis B, Chronic
- PEGylated recombinant human interferon alpha-2b injection
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of Anhui Medical University
Jun 24, 2023
Hepatitis B, Chronic Trial in Hong Kong, Korea, Republic of, Taiwan (EYP001a, Entecavir, Pegylated interferon alpha2a)
Active, not recruiting
- Hepatitis B, Chronic
- EYP001a
- +2 more
-
Hong Kong, Hong Kong
- +5 more
Sep 27, 2021
Hematological Tumors, Recurrence Trial in Shanghai (Peg interferon alfa-2b)
Recruiting
- Hematological Neoplasms
- Recurrence
- Peg interferon alfa-2b
-
Shanghai, Shanghai, ChinaShanghai Jiao Tong University Affilated First People's Hospital
Oct 10, 2021
Hepatitis B, Chronic Trial in Guangzhou (pegylated interferon-alfa)
Recruiting
- Hepatitis B, Chronic
- pegylated interferon-alfa
-
Guangzhou, Guangdong, ChinaDepartment of Infectious Diseases, The Third Affliated Hospital
Dec 20, 2021
Relapsing Remitting Multiple Sclerosis (RRMS) Trial in Tehran (Pegylated interferon beta-1a, Interferon Beta-1A Prefilled
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Pegylated interferon beta-1a
- Interferon Beta-1A Prefilled Syringe
-
Tehran, Iran, Islamic Republic ofSina Hospital
Feb 5, 2022